ERYTECH to Present Pharmacodynamic Data from Phase 2/3 Trial of Eryaspase in ALL at ASCO 2018

ERYTECH Pharma (Euronext: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will present pharmacodynamic characterization data from its Phase 2/3 trial of eryaspase (GRASPA®) in combination with chemotherapy for the treatment of relapsed acute lymphoblastic leukemia (ALL) at the American Society of Clinical Oncology (ASCO) Annual Meeting, being held June 1-5, 2018 in Chicago, Illinois.

Menu